Evidence map›Paper›PMID 38047701›Full record

ArticleMicrobiology spectrum2024

Pharmacokinetic and pharmacodynamic evaluation of the atypical tetracyclines chelocardin and amidochelocardin in murine infection models.

Katharina Rox, Rolf Jansen, Tadeja Lukežič, Marina Greweling-Pils, Jennifer Herrmann, Marcus Miethke, Stephan Hüttel, Fabienne Hennessen, Antoine Abou Fayad, Cornelia Holzhausen and 8 more

Open access · goldAbstract read
In one paragraph

Article in Microbiology spectrum, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 4 institutions in 3 countries.

Katharina RoxDepartment of Chemical Biology, Helmholtz Centre for Infection Research (HZI) , Braunschweig, Germany.ORCID 0000-0002-8020-1384
Rolf JansenDepartment of Microbial Drugs, Helmholtz Centre for Infection Research (HZI) , Braunschweig, Germany.
Tadeja LukežičGerman Centre for Infection Research (DZIF), Partner Site Braunschweig-Hannover , Braunschweig, Germany.
Marina Greweling-PilsMouse Pathology, Helmholtz Centre for Infection Research (HZI) , Braunschweig, Germany.
Jennifer HerrmannGerman Centre for Infection Research (DZIF), Partner Site Braunschweig-Hannover , Braunschweig, Germany.
Marcus MiethkeGerman Centre for Infection Research (DZIF), Partner Site Braunschweig-Hannover , Braunschweig, Germany.
Stephan HüttelGerman Centre for Infection Research (DZIF), Partner Site Braunschweig-Hannover , Braunschweig, Germany.
Fabienne HennessenGerman Centre for Infection Research (DZIF), Partner Site Braunschweig-Hannover , Braunschweig, Germany.
Antoine Abou FayadGerman Centre for Infection Research (DZIF), Partner Site Braunschweig-Hannover , Braunschweig, Germany.
Cornelia HolzhausenMouse Pathology, Helmholtz Centre for Infection Research (HZI) , Braunschweig, Germany.
Carina Vingsbo LundbergStatens Serum Institut , Copenhagen, Denmark.
Joanne TeagueEvotec Ltd , Manchester, United Kingdom.
Enge SudarmanDepartment of Microbial Drugs, Helmholtz Centre for Infection Research (HZI) , Braunschweig, Germany.
Lisa BülterGerman Centre for Infection Research (DZIF), Partner Site Braunschweig-Hannover , Braunschweig, Germany.
Thomas HesterkampGerman Centre for Infection Research (DZIF), Partner Site Braunschweig-Hannover , Braunschweig, Germany.
Marc StadlerGerman Centre for Infection Research (DZIF), Partner Site Braunschweig-Hannover , Braunschweig, Germany.
Mark BrönstrupDepartment of Chemical Biology, Helmholtz Centre for Infection Research (HZI) , Braunschweig, Germany.ORCID 0000-0002-8971-7045
Rolf MüllerGerman Centre for Infection Research (DZIF), Partner Site Braunschweig-Hannover , Braunschweig, Germany.ORCID 0000-0002-1042-5665
German Center for Infection Research · DEHelmholtz Centre for Infection Research · DEEvotec (United Kingdom) · GBStatens Serum Institut · DK

Funding

Deutsches Zentrum für Infektionsforschung (DZIF) TTU 09.710Deutsches Zentrum für Infektionsforschung (DZIF) TTU 09.814Deutsches Zentrum für Infektionsforschung (DZIF) TTU 09.821
6 · The paper itself

Abstract

importanceThere is a strong need to find novel treatment options against urinary tract infections associated with antimicrobial resistance. This study evaluates two atypical tetracyclines, namely chelocardin (CHD) and amidochelocardin (CDCHD), with respect to their pharmacokinetics and pharmacodynamics. We show CHD and CDCHD are cleared at high concentrations in mouse urine. Especially, CDCHD is highly effective in an ascending urinary tract infection model, suggesting further preclinical evaluation.

Indexed as

Anti-Bacterial AgentsUrinary Tract InfectionsAnimalsMiceMicrobial Sensitivity TestsTetracyclinesAnti-Bacterial AgentschelocardinTetracyclinesamidochelocardinchelocardinEscherichia coliKlebsiella pneumoniaeneutropenic thigh infectionPK/PDtetracyclineurinary tract infection

Identifiers

PMID38047701
PMCPMC10783034
OpenAlexW4389294787

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.